A share price of Arcutis Biotherapeutics Inc [ARQT] is currently trading at $25.31, up 1.57%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ARQT shares have gain 25.86% over the last week, with a monthly amount glided 19.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcutis Biotherapeutics Inc [NASDAQ: ARQT] stock has seen the most recent analyst activity on July 25, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $18. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 30, 2024, and set its price target to $19. On August 28, 2024, Jefferies initiated with a Buy rating and assigned a price target of $15 on the stock. Mizuho upgraded its rating to a Buy and increased its price target to $8 on January 03, 2024. Mizuho downgraded its rating to a Neutral and reduced its price target to $4 on October 26, 2023. Goldman downgraded its rating to Neutral for this stock on October 13, 2023, and downed its price target to $6. In a note dated September 07, 2022, Needham initiated a Buy rating and provided a target price of $46 on this stock.
Arcutis Biotherapeutics Inc experienced fluctuations in its stock price throughout the past year between $8.21 and $27.08. Currently, Wall Street analysts expect the stock to reach $30.33 within the next 12 months. Arcutis Biotherapeutics Inc [NASDAQ: ARQT] shares were valued at $25.31 at the most recent close of the market. An investor can expect a potential return of 19.83% based on the average ARQT price forecast.
Analyzing the ARQT fundamentals
Trailing Twelve Months sales for Arcutis Biotherapeutics Inc [NASDAQ:ARQT] were 317.93M which represents 121.69% growth. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.12%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.3 and Total Capital is -0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.77 points at the first support level, and at 24.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.70, and for the 2nd resistance point, it is at 26.10.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Arcutis Biotherapeutics Inc [NASDAQ:ARQT] is 3.50. In addition, the Quick Ratio stands at 3.28 and the Cash Ratio stands at 0.47. Considering the valuation of this stock, the price to sales ratio is 9.75, the price to book ratio is 19.26.
Transactions by insiders
Recent insider trading involved Watanabe Todd, that happened on Oct 28 ’25 when 40000.0 shares were sold. officer, Todd F watanabe completed a deal on Oct 28 ’25 to buy 40000.0 shares. Meanwhile, Edwards Larry Todd sold 4504.0 shares on Oct 02 ’25.
